# Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis

> **NCT00581100** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 136 (actual)

## Conditions studied

- Nail Psoriasis
- Plaque Psoriasis

## Interventions

- **DRUG:** etanercept

## Key facts

- **NCT ID:** NCT00581100
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-08
- **Final completion:** 2009-10
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2013-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581100, "Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT00581100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*